By Fineline Cube 
WuXi AppTec (Shanghai) Co., Ltd., a wholly‑owned subsidiary of Wuxi AppTec Co., Ltd. (SHA: 603259, HKG: 2359), today announced the closing of a sale‑and‑purchase agreement with Hillhouse Investment Management (Hillhouse). Under the deal, WuXi AppTec will divest all shares in WuXi Clinical Development Services (Shanghai) Co., Ltd. (“WuXi Clinical”) and WuXi MedKey Med‑Tech Development (Shanghai) Co., Ltd. (“WuXi MedKey”) for a total cash consideration of RMB 2.8 billion.
Strategic Rationale
- Core CRDMO Focus – The transaction aligns with WuXi AppTec’s long‑term strategy to sharpen its core Contract Research, Development, Manufacturing, and Outsourcing (CRDMO) model, prioritising drug discovery, laboratory testing, process development and manufacturing services.
- Portfolio Consolidation – By divesting the China‑based clinical research entities, WuXi AppTec will streamline its operations and re‑allocate capital to high‑growth platform businesses.
Financial Impact (Jan‑Sep 2025, Unaudited)
| Metric | WuXi Clinical & MedKey | % of Group (Q1‑Q3 2025) |
|---|---|---|
| Revenue | RMB 1.16 bn | 3.5 % |
| Net Profit | RMB 0.09 bn | 0.7 % |
The sale is expected to have a minimal impact on the group’s consolidated performance, given the modest contribution of the divested entities to overall revenue and earnings.
Deal Details
- Transaction Value – RMB 2.8 bn in cash.
- Buyer – Hillhouse Investment Management, a leading investment arm with a focus on life‑science enterprises.
- Seller – WuXi AppTec (Shanghai) Co., Ltd., a wholly‑owned subsidiary of Wuxi AppTec Co., Ltd.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech